Comparative study about Pharmacoeconomic guidelines across South East Asian countries

Abstract

Background: Pharmacoeconomics (PE) is the comparative study thatdeals with comparing one drug or therapy or technology to the other. It forms the most important constituent of providing affordable healthcare in many countries. Many SouthEast Asian countries have their own pharmcoeconomic guidelines.

Method:The study compares various parameters of pharmacoeconomic guidelines of a few SouthEast Asian countries. The data regarding pharmacoeconomic guidelines for Taiwan, Malaysia, Japan, South Korea and Thailandwere obtained from the ISPOR webpage. Various parameters of the guidelines among SouthEast Asian countries were compared.

Result: Pharmacoeconomic guidelines in the Southeast Asian countries(Taiwan, Malaysia, Japan, South Korea, Thailand) were compared on the basis of target population, source of costs, costs to be included, preference of effectiveness over efficacy, discounting costs, sensitivity analysis, total cost vs effectiveness, financial impact, mandatory, recommended or voluntary implementation of the guidelines. It was found that Thailand and South Korea didn’t not have any pharmacoeconomic guidelines in place. The guidelines are mandatory in Japan whereas voluntary in Malaysia and Taiwan. While Japan shows the most systematically formed PE guidelines, Malaysia comes second. In Japan the costs are incurred by the public insurers and the local governments

Conclusion: The various pharmaco-economic guidelines across Asia and the rest of the world were then compared to the upcoming pharmaco economic guidelines in India. Started by the current prime minister of India Shri. Narendra Modi.

Reference: https://tools.ispor.org/peguidelines/COMP3.asp